Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-INCLINE in atrial fibrillation unsuitable for oral anticoagulation
2025-521618-25-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) comparing Cenvacibart, Amrecibart and Placebo (3 arms). Primary endpoints: Time to first occurrence of ischemic stroke or systemic embolism and Time to first occurrence of ISTH major bleeding. Planned start Sep 2026; status: authorised.
02
Drugs
cenvacibartamrecibart
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2025-521618-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521618-25-00.